Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.71 |
| ▸ | FYN | P06241 | 7/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.55 |
| ▸ | USP7 | Q93009 | 3/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620369 | 0.88 | USP7 (0.73) | CHEK2FYNMAP4K4USP7 | |
| SCHEMBL4620478 | 0.83 | CHEK2 (1.00) | CHEK2FYNMAP4K4MKNK1 | |
| SCHEMBL4470993 | 0.82 | CHEK2 (0.56) | CHEK2FYNTAAR1MAP4K4USP7 | |
| SCHEMBL4619476 | 0.82 | CHEK2 (0.64) | CHEK2FYNMAP4K4USP7MKNK1 | |
| SCHEMBL29817852 | 0.79 | TAAR1 (1.00) | CHEK2TAAR1MAP4K4 | |
| SCHEMBL3787868 | 0.79 | TAAR1 (1.00) | CHEK2TAAR1MAP4K4 | |
| SCHEMBL18613285 | 0.79 | FYN (1.00) | CHEK2FYN | |
| SCHEMBL30521772 | 0.79 | FYN (1.00) | CHEK2FYN | |
| SCHEMBL4619240 | 0.76 | FYN (1.00) | FYN | |
| SCHEMBL4173910 | 0.76 | NTRK1 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962623-B2 | Aminopyrazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140187529-A1 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2012121939-A2 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187529-A1 | AMINOPYRAZINE COMPOUNDS | ITK, IL4I1, IL5 | CHEK2 3233/4885FYN 709/4885TAAR1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.